Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15416353 | 0.84 | MPO (0.50) | MPOACHE | |
| SCHEMBL15431350 | 0.84 | MPO (0.50) | MPOACHE | |
| SCHEMBL2033499 | 0.84 | MPO (0.46) | MPO | |
| SCHEMBL30796037 | 0.81 | KDM5A (0.33) | C5AR1ACHE | |
| SCHEMBL22097906 | 0.81 | KDM5A (0.33) | ALDH1A1C5AR1ACHE | |
| SCHEMBL633451 | 0.81 | OGA (0.41) | ALDH1A1KMT2AC5AR1 | |
| SCHEMBL670597 | 0.79 | — | — | |
| SCHEMBL2358200 | 0.78 | MPO (0.58) | MPOACHE | |
| SCHEMBL659820 | 0.78 | MPO (0.50) | MPOACHE | |
| SCHEMBL659819 | 0.78 | MPO (0.50) | MPOACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648763-A2 | COMPOUNDS FOR FGFRS INHIBITORS | Cogent Biosciences, Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| CN-114341127-B | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240270741-A1 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. | 2024-08-15 | — | — | US | disclosed |
| WO-2024151638-A2 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151638-A2 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| CN-116490186-A | Compounds for targeted degradation of RET | C4医药公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4192458-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-2265270-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010121036-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010121036-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| WO-2010059771-A1 | SUBSTITUTED PYRROLO[2,3-B]-PYRIDINES AND-PYRAZINES | OSI PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2009099982-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270741-A1 | COMPOUNDS FOR FGFRS INHIBITORS | FGFR1, FGFR3, FGFR2 | MPO 4883/4885ALDH1A1 1514/4885KMT2A 1502/4885 |
| US-20100267668-A1 | 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CXCR2 | MPO 897/4885ALDH1A1 576/4885KMT2A 976/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | MPO 4352/4885ALDH1A1 3400/4885KMT2A 1132/4885 |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | MPO 4641/4885ALDH1A1 945/4885KMT2A 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.